CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

What happened: CRISPR Therapeutics reported third quarter 2026 results, with CASGEVY revenue of $99 million and new regulatory approvals for younger children in the U.K., United Arab Emirates, and Bahrain. Why it matters: The company said CASGEVY is reaching more patients, including younger children, and that the RMAT designations underscore CTX310's potential in cardiovascular disease. Management described the coming weeks of clinical data and completed Phase 2 enrollment in CTX611 as a pivotal period for the pipeline. Market: -2.8% today ($49.99), -7.0% YTD, 0.7x vol — as of 22:32 UTC

CRISPR Therapeutics reported third quarter 2026 results, with CASGEVY revenue of $99 million and new regulatory approvals for younger children in the U.K., United Arab Emirates, and Bahrain.

The company said CASGEVY is reaching more patients, including younger children, and that the RMAT designations underscore CTX310's potential in cardiovascular disease. Management described the coming weeks of clinical data and completed Phase 2 enrollment in CTX611 as a pivotal period for the pipeline. Market: -2.8% today ($49.99), -7.0% YTD, 0.7x vol — as of 22:32 UTC